Evommune (NYSE: EVMN) widens Q2 2026 loss but reports $288M cash runway
Rhea-AI Filing Summary
Evommune, Inc., a clinical-stage biotechnology company, reported second quarter 2026 results and highlighted progress across its inflammatory disease pipeline. Lead oral candidate EVO756 is in a fully enrolled Phase 2b trial in moderate-to-severe atopic dermatitis, with top-line data expected in September 2026, and a global Phase 2b migraine prophylaxis trial has recently begun, targeting top-line data in 2027. After a Phase 2b chronic spontaneous urticaria study failed to meet its primary endpoint, development of EVO756 in that indication was discontinued to prioritize atopic dermatitis and migraine. Injectable fusion protein EVO301 showed positive Phase 2a data in atopic dermatitis, with full results to be presented at an upcoming medical conference and a Phase 2b trial planned to start in mid-2027, while additional indications such as ulcerative colitis and certain cardiovascular-related inflammatory conditions are being evaluated.
For the quarter ended June 30, 2026, revenue was zero, research and development expense was $26.4 million, and general and administrative expense was $8.5 million, leading to a net loss of $32.2 million. For the first six months of 2026, net loss was $53.9 million. Cash, cash equivalents and investments totaled $288.0 million as of June 30, 2026, compared with $216.7 million at December 31, 2025, and the company states this provides cash runway through 2028.
Positive
- Evommune reported $288.0 million in cash, cash equivalents and investments as of June 30, 2026, up from $216.7 million at December 31, 2025, and stated this provides cash runway through 2028.
Negative
- Quarterly net loss increased to $32.2 million for the three months ended June 30, 2026, with a six-month net loss of $53.9 million versus $28.1 million in the prior-year period.
Filing Explained
June 30 liquidity was split between $200,793 thousand in cash, equivalents and short-term investments and $87,214 thousand in long-term investments.
Evommune reports second-quarter results and business updates in this August 6 Form 8-K, a form used to report specified material events. The disclosure is current as a furnished report under Item 2.02.
The Item 2.02 information, including the press release, is furnished rather than filed and is not incorporated by reference into another SEC filing unless expressly stated. As of
8-K Event Classification
Key Figures
Key Terms
Phase 2b dose-ranging clinical trial medical
Eczema Area and Severity Index (EASI) medical
Pruritus-NRS medical
chronic spontaneous urticaria (CSU) medical
monthly migraine days (MMD) medical
Earnings Snapshot
The company states that its cash, cash equivalents and investments as of June 30, 2026 provide cash runway through 2028.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Evommune (EVMN) revenues and net loss for Q2 2026?
How much cash runway does Evommune (EVMN) have after Q2 2026?
What are the key upcoming milestones for EVO756 at Evommune (EVMN)?
What happened in Evommune (EVMN)'s chronic spontaneous urticaria (CSU) trial?
What is the status of Evommune (EVMN)'s EVO301 program in atopic dermatitis?
How did Evommune (EVMN)'s operating expenses change in Q2 2026?
Did Evommune (EVMN) generate any collaboration revenue in the first half of 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, Evommune, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the second quarter ended June 30, 2026 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference.
The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly stated in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
|
Description |
99.1 |
|
Press Release dated August 6, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Evommune, Inc. |
|
|
|
|
|
Date: August 6, 2026 |
|
By: |
/s/ Luis Peña |
|
|
|
Luis Peña |
|
|
|
President and Chief Executive Officer |
2
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026
‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027
‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference
‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline
PALO ALTO, Calif. & NEW YORK, August 6, 2026 – Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.
"There are still no first-line oral options for patients suffering with AD that combine lesion control, itch relief and tolerability. That gap is where we believe EVO756 can make a difference, as it targets neurogenic mast cell biology and non-histaminergic itch. We are excited to deliver top-line Phase 2b data next month. We also believe the underlying biology and market opportunity are especially compelling in migraine prophylaxis and that EVO756 could define the next wave of preventative treatments. We are very excited to have the Phase 2b trial now underway and expect top-line data next year,” said Luis Peña, President and Chief Executive Officer at Evommune. “Taken together, these milestones reflect the continued execution of our mission-driven approach to developing transformative therapies for people living with immune-mediated diseases."
Recent Business Highlights and Upcoming Milestones
EVO756 – Oral MRGPRX2 Antagonist Program
Potential first and best-in-class, potent and highly selective small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on both mast cells and peripheral sensory neurons. This dual expression allows MRGPRX2 to uniquely modulate the neurogenic inflammation feedback loop between nerves and immune cells that drive chronic inflammation.
EVO301 – Injectable IL-18 Binding Protein Fusion Protein Program
Long-acting fusion protein consisting of an IL-18 binding protein and an anti-serum albumin Fab-associated domain with potential for more effective distribution to inflamed tissues than traditional monoclonal antibodies.
Second Quarter 2026 Financial Results
About Evommune, Inc.
Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements.” These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of EVO756 and EVO301, and the design, objectives, initiation, timing, progress and results of the Phase 2b clinical trials evaluating EVO756 AD and in migraine and the Phase 2b trial evaluating EVO301 in AD; anticipated cash runway through 2028; and continued advancement of the Company's portfolio. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K, filed with the SEC on March 5, 2026, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Evommune, Inc. |
|
||||||||||||||||||
Unaudited Condensed Consolidated Statements of Operations |
|
||||||||||||||||||
(in thousands, except share and per share data) |
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||||||
|
June 30, |
|
|
June 30, |
|
||||||||||||||
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||||||
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
License revenue |
$ |
|
— |
|
|
$ |
|
— |
|
|
$ |
|
— |
|
|
$ |
|
3,000 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
26,412 |
|
|
|
|
19,638 |
|
|
|
|
43,731 |
|
|
|
|
34,000 |
|
General and administrative |
|
|
8,483 |
|
|
|
|
3,356 |
|
|
|
|
15,118 |
|
|
|
|
7,026 |
|
Total operating expenses |
|
|
34,895 |
|
|
|
|
22,994 |
|
|
|
|
58,849 |
|
|
|
|
41,026 |
|
Loss from operations |
|
|
(34,895 |
) |
|
|
|
(22,994 |
) |
|
|
|
(58,849 |
) |
|
|
|
(38,026 |
) |
Total other income, net |
|
|
2,649 |
|
|
|
|
9,429 |
|
|
|
|
4,929 |
|
|
|
|
9,904 |
|
Net loss |
|
|
(32,246 |
) |
|
|
|
(13,565 |
) |
|
|
|
(53,920 |
) |
|
|
|
(28,122 |
) |
Basic and diluted net loss per share of common stock |
$ |
|
(0.89 |
) |
|
$ |
|
(8.80 |
) |
|
$ |
|
(1.54 |
) |
|
$ |
|
(18.29 |
) |
Weighted average basic and diluted shares of common stock outstanding |
|
|
36,135,644 |
|
|
|
|
1,540,695 |
|
|
|
|
34,908,631 |
|
|
|
|
1,537,828 |
|
Evommune, Inc. |
|
|||||||||
Unaudited Condensed Consolidated Balance Sheets |
|
|||||||||
(in thousands) |
|
|||||||||
|
|
|
|
|
|
|
|
|
||
|
|
June 30, |
|
|
December 31, |
|
||||
|
|
2026 |
|
|
2025 |
|
||||
Cash, cash equivalents and short-term investments |
|
$ |
|
200,793 |
|
|
$ |
|
149,200 |
|
Other current assets |
|
|
|
3,453 |
|
|
|
|
4,278 |
|
Long-term investments |
|
|
|
87,214 |
|
|
|
|
67,489 |
|
Other non-current assets |
|
|
|
10,487 |
|
|
|
|
3,979 |
|
Total assets |
|
$ |
|
301,947 |
|
|
$ |
|
224,946 |
|
|
|
|
|
|
|
|
|
|
||
Current liabilities |
|
$ |
|
17,487 |
|
|
$ |
|
17,909 |
|
Other non-current liabilities |
|
|
|
6,874 |
|
|
|
|
1,471 |
|
Total liabilities |
|
|
|
24,361 |
|
|
|
|
19,380 |
|
Total stockholders’ equity |
|
|
|
277,586 |
|
|
|
|
205,566 |
|
Total liabilities and stockholders’ equity |
|
$ |
|
301,947 |
|
|
$ |
|
224,946 |
|
Contacts:
Media:
Paul Laland
Paul.laland@evommune.com
Investors:
Sarah McCabe
investors@evommune.com